Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine

British Journal of Haematology

Volumn 122, Issue 1, 2003, Pages 53-60

  Galmarini, Carlos María ^a,c   Thomas, Xavier ^a   Graham, Kathryn ^b   El Jafaari, Assia ^a   Cros, Emeline ^a   Jordheim, Lars ^a   Mackey, John R ^b   Dumontet, Charles ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CROSS CANCER INSTITUTE   (Canada)

^c INSERM   (France)

Author keywords

5 nucleotidase; Cytarabine; Deoxycytidine kinase; Drug resistance; Leukaemia

Indexed keywords

5' NUCLEOTIDASE; ANTHRACYCLINE; CYTARABINE; DEOXYCYTIDINE KINASE; ETOPOSIDE; MESSENGER RNA; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; ARTICLE; BLAST CELL; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INACTIVATION; FEMALE; GENE EXPRESSION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE;

EID: 0038007346     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04386.x     Document Type: Article

References (35)

1. Amici, A. & Magni, G. (2002) Human erythrocyte pyrimidine 5′-nucleotidase, PN-I. Archives of Biochemistry and Biophysics, 397, 184-190.
2. Beckwith, M., Urba, W.J. & Longo, D.L. (1993) Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. Journal of the National Cancer Institute, 85, 483-488.
3. Coleman, C.N., Stoller, R.G., Drake, J.C. & Chabner, B.A. (1975) Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. Blood, 46, 791-803.
4. Colly, L.P., Peters, W.G., Richel, D., Arentsen-Honders, M.W., Starrenburg, C.W. & Willemze, R. (1987) Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukaemia. Seminars in Oncology, 14, 257-261.
5. Dumontet, C., Fabianowska-Majewska, K., Mantincic, D., Callet Bauchu, E., Tigaud, I., Gandhi, V., Lepoivre, M., Peters, G.J., Rolland, M.O., Wyczechowska, D., Fang, X., Gazzo, S., Voorn, D.A., Vanier-Viornery, A. & Mackey, J.R. (1999) Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. British Journal of Haematology, 106, 78-85.
6. Flasshove, M., Strumberg, D., Ayscue, L., Mitchell, B.S., Tirier, C., Heit, W., Seeber, S. & Schutte, J. (1994) Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukaemia and resistance to cytosine arabinoside. Leukaemia, 8, 780-785.
7. Galmarmi, C.M., Graham, K., Thomas, X., Calvo, F., Rousselot, P., El Jafaari, A., Cros, E., Mackey, J.R. & Dumontet, C. (2001a) Expression of high Km 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukaemia. Blood, 98, 1922-1926.
8. Galmarini, C.M., Mackey, J.R. & Dumontet, C. (2001b) Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukaemia, 15, 875-890.
9. Galmarini, C.M., Mackey, J.R. & Dumontet, C. (2002a) Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncology, 3, 415-424.
10. Galmarini, C.M., Thomas, X., Calvo, F., Rousselot, P., Rabilloud, M., El Jaffari, A., Cros, E. & Dumontet, C. (2002b) In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. British Journal of Haematology, 117, 860-868.
11. Gunji, H., Kharbanda, S. & Kufe, D. (1991) Induction of internucleosomal DNA fragmentation in human myeloid leukaemia cells by 1-beta-D-arabinofuranosylcytosine. Cancer Research, 51, 741-743.
12. Jahns-Streubel, G., Reuter, C., Unterhalt, M., Schleyer, E., Wormann, B., Buchner, T. & Hiddemann, W. (1995) Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukaemia. Leukaemia, 9, 1857-1863.
13. Jahns-Streubel, G., Reuter, C., Auf der Landwehr, U., Unterhalt, M., Schleyer, E., Wormann, B., Buchner, T. & Hiddemann, W. (1997) Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukaemia. Blood, 90, 1968-1976.
14. Kawasaki, H., Carrera, C.J., Piro, L.D., Saven, A., Kipps, T.J. & Carson, D.A. (1993) Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood, 81, 597-601.
15. Kufe, D.W., Major, P.P., Egan, E.M. & Beardsley, G.P. (1980) Correlation of cytotoxicity with incorporation of ara-C into DNA. Journal of Biological Chemistry, 255, 8997-9000.
16. Kufe, D.W., Weichselbaum, R., Egan, E.M., Dahlberg, W. & Fram, R.J. (1984) Lethal effects of 1-beta-D-arabinofuranosylcytosine incorporation into deoxyribonucleic acid during ultraviolet repair. Molecular Pharmacology, 25, 322-326.
17. Lange, B.J., Kobrinsky, N., Barnard, D.R., Arthur, D.C., Buckley, J.D., Howells, W.B., Gold, S., Sanders, J., Neudorf, S., Smith, F.O. & Woods, W.G. (1998) Distinctive demography, biology, and outcome of acute myeloid leukaemia and myelodysplastic syndrome in children with Down syndrome. Children's Cancer Group Studies 2861 and 2891. Blood, 91, 608-615.
18. Liliemark, J.O., Plunkett, W. & Dixon, D.O. (1985) Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5′-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine. Cancer Research, 45, 5952-5957.
19. Lotfi, K., Mansson, E., Chandra, J, Wang, Y., Xu, D., Knaust, E., Spasokoukotskaja, T., Liliemark, E., Eriksson, S. & Albertioni, F. (2001) Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide. British Journal of Haematology, 113, 339-346.
20. Major, P.P., Egan, E.M., Beardsley, G.P., Minden, M.D. & Kufe, D.W. (1981) Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proceedings of the National Academy of Science of the United States of America, 78, 3235-3239.
21. Mansson, E., Spasokoukotskaja, T., Sallstrom, J., Eriksson, S. & Albertioni, F. (1999) Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line. Cancer Research, 59, 5956-5963.
22. Momparler, R.L., Eliopoulos, N., Bovenzi, V., Letourneau, S., Greenbaum, M. & Cournoyer, D. (1996) Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells. Cancer Gene Therapy, 3, 331-338.
23. Pieters, R., Huismans, D.R., Loonen, A.H., Peters, G.J., Hahlen, K., van der Does-van den Berg, A., van Wering, E.R. & Veerman, A.J. (1992) Relation of 5′-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukaemia. Leukaemia Research, 16, 873-880.
24. Plagemann, P.G., Marz, R. & Wohlhueter, R.M. (1978) Transport and metabolism of deoxycytidine and 1-beta-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis. Cancer Research, 38, 978-989.
25. Rampazzo, C., Gazziola, C., Ferraro, P., Gallinaro, L., Johansson, M., Reichard, P. & Bianchi, V. (1999) Human high-Km 5′-nucleotidase effects of overexpression of the cloned cDNA in cultured human cells. European Journal of Biochemistry, 261, 689-697.
26. Ravindranath, Y., Abella, E., Krischer, J.P., Wiley, J., Inoue, S., Harris, M., Chauvenet, A., Alvarado, C.S., Dubowy, R. & Ritchey, A.K. (1992) Acute myeloid leukaemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood, 80, 2210-2214.
27. Reichard, P. (1988) Interactions between deoxyribonucleotide and DNA synthesis. Annual Review of Biochemistry, 57, 349-374.
28. Rustum, Y.M. & Raymakers, R.A. (1992) 1-Beta-arabinofuranosylcytosine in therapy of leukaemia: preclinical and clinical overview. Pharmacology and Therapeutics, 56, 307-321.
29. Schirmer, M., Stegmann, A.P., Geisen, F. & Konwalinka, G. (1998) Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5′-nucleotidase activity. Experimental Hematology, 26, 1223-1228.
30. Shewach, D.S., Reynolds, K.K. & Hertel, L. (1992) Nucleotide specificity of human deoxycytidine kinase. Molecular Pharmacology, 42, 518-524.
31. Tattersall, M.H., Ganeshaguru, K. & Hoffbrand, A.V. (1974) Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside. British Journal of Haematology, 27, 39-46.
32. Taub, J.W., Matherly, L.H., Stout, M.L., Buck, S.A., Gurney, J.G. & Ravindranath, Y. (1996) Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukaemia. Blood, 87, 3395-3403.
33. Taub, J.W., Huang, X., Matherly, L.H., Stout, M.L., Buck, S.A., Massey, G.V., Becton, D.L., Chang, M.N., Weinstein, H.J. & Ravindranath, Y. (1999) Expression of chromosome 21-localized genes in acute myeloid leukaemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood, 94, 1393-1400.
34. Veuger, M.J., Honders, M.W., Landegent, J.E., Willemze, R. & Barge, R.M. (2000) High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukaemia. Blood, 96, 1517-1524.
35. Zipursky, A., Thorner, P., De Harven, E., Christensen, H. & Doyle, J. (1994) Myelodysplasia and acute megakaryoblastic leukaemia in Down's syndrome. Leukaemia Research, 18, 163-171.